


Pembrolizumab KEYNOTE-522

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



Pembrolizumab KEYNOTE-522

### FINAL SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence

Experimental Arm: Pembrolizumab + ChT (paclitaxel + carboplatin)

Control Arm: Placebo plus ChT (paclitaxel + carboplatin)



